KEY INVESTOR INFORMATION This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest. VanEck Bionic Engineering UCITS ETF (the "Fund") a sub-fund of VanEck UCITS ETFs plc (the "Company") Share Class: USD A ISIN: IE0005TF96I9 This Fund is managed by VanEck Asset Management B.V., a subsidiary of Van Eck Associates Corporation. Objectives and Investment Policy (including equity swaps and swaps on the Index), currency forwards and non- The Fund’s investment objective is to replicate, before fees and expenses, the deliverable forwards (a forward contract that does not require settlement on MVIS® Global Bionic Healthcare ESG Index (the “Index”). maturity) (NDFs). The Fund may also invest in ancillary liquid assets and money In order to seek to achieve its investment objective, the Manager will normally market instruments which may include bank deposits, depositary receipts, use a replication strategy by investing directly in the underlying equity securities certificates of deposit, fixed or floating rate instruments (treasury bills), of the Index being stock, American depository receipts (ADRs), and globalcommercial paper, floating rate notes and freely transferable promissory notes. depository receipts (GDRs) that consists of the component securities of the The ancillary liquid assets, money market instruments and FDI (other than Index. Such equity securities which form part of the Index are required to bepermitted unlisted investments) will be listed or traded on the Markets referred to issued by companies who generate at least 50% (25% for current components) in Appendix II of the Prospectus. of their revenues from medical, dental or vision-related implants, bioprinting, The Fund may not invest more than 10% of its Net Asset Value in open-ended prosthesis, or preservation of organs and tissue. This does not include collective investment. companies involved in implantable or wearable devices or materials used only for Furthermore, the Fund may not invest less than 51% of its Net Asset Value in cosmetic purposes. Such equity securities must be listed or traded on theequity securities which constitute "equity participation" within the meaning of Markets referred to in Appendix II of the Prospectus.section 2, Article 8 of the German Investment Tax Act. The Manager has categorised the Product as meeting the provisions set out in Article 9(1) of Regulation (EU) 2019/2088 on sustainability related disclosures in The Fund, using a “passive” or indexing investment approach, attempts to the financial services sector ("SFDR") for products, which have sustainable approximate the investment performance of the Index by investing in a portfolio of investment as their objective and where an index has been designated as asecurities that generally replicates the Index. The Investment Manager will reference benchmark. The Index considers ESG factors as further detailed in the regularly monitor the Fund’s tracking accuracy. Index methodology available on the Index Provider’s website and in the Recommendation: This Fund may not be appropriate for investors who plan to Prospectus. withdraw their money within 5 years. Where it is not practical or cost efficient for the Fund to fully replicate the Index, • Fund’s base currency: U.S. Dollar the Manager may utilise an optimised sampling methodology. • Distribution policy: Income accumulated The Fund may also (or alternatively) invest in financial derivative instruments The shares are admitted for trading on various stock exchanges and can be (FDIs) which relate to the Index or constituents of the Index. traded on the secondary market. The price of the shares offered on the The Fund may invest up to 15% of its Net Asset Value directly in shares issued secondary market may deviate from the net asset value of the shares. The return by companies listed on the Shanghai Stock Exchange or the Shenzhen Stock of the Fund is directly related to the return of the underlying assets minus the Exchange. The Fund may invest more than 20% of its Net Asset Value incosts associated with the Fund. If the performance of the underlying assets emerging markets.decreases, the performance of the Fund will also decrease. There is no capital The FDIs which the Fund may use are futures, options (puts and calls), swaps protection against Market Risk. Risk and Reward Profile Lower riskHigher risk Liquidity Risks: Exists when a particular financial instrument is difficult to Typically lower reward Typically higher reward purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all. 1 23 4 56 7 Equity Market Risk: The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including The risk and reward indicator is calculated using historical and simulated general economic conditions and sudden and unpredictable drops in historical data. Historical data may not be a reliable indication for the future. value. An investment in the Fund may lose money. Therefore, the risk classification may change over time. Industry or Sector Concentration Risk: The Fund’s assets may be Even if the Fund is in the lowest risk category, it does not mean it is risk free orconcentrated in one or more particular sectors or industries. The Fund that capital is guaranteed or protected.may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively This Fund is ranked at 7 because funds of this type have experienced very high impact the Fund's performance to a greater extent than if the Fund’s rises and falls in value in the past. assets were invested in a wider variety of sectors or industries. The following risks can be materially relevant but are not necessarily adequately captured by the synthetic risk indicator and may cause additional loss: For more information on risks, please see the “Risk Factors” section of the Fund’s prospectus, available on www.vaneck.com. Charges The charges you pay are used to pay the costs of running the Fund, including *Not applicable to investors on the secondary market. Investors who buy or sell the costs of marketing and distributing it. These charges reduce the potential shares via a market pay the costs charged by their financial intermediaries. growth of your investment. Information on these charges can be obtained from the markets where the shares are listed and traded or from the financial intermediaries. One-off charges taken before or after you invest Entry charge None* You can find more information on the charges in the cost section of the Fund’s prospectus and/or supplement. This is available at www.vaneck.com. Exit charge None* The ongoing charges figure is based on expenses for the 12-month period ending These are the maximum charges that could be taken from your money before it 31 December 2024. This figure may vary from year to year. It excludes portfolio is invested or before we pay out the sale proceeds of your investment. transaction costs. Charges taken from the Fund over a year Ongoing charges 0.55% Charges taken from the Fund under certain specific conditions Performance fee None Past Performance 10 % ​5.1%5.1%​4.6% 4.6%50 ​-0.4%-0.4% ​-0.9%-0.9% -5 202020212022 20232024Fund Index Any indication of past performance is not a reliable indicator of future performance. The chart shows the Fund’s annual performance in USD for each full calendar year over the period displayed in the chart. It is expressed as a percentage change of the Fund’s net asset value at each year-end. The Fund was launched on 02 December 2022. Performance is shown after deduction of ongoing charges. Practical Information The Depositary of the Fund is State Street Custodial Services (Ireland) Limited.remuneration committee, where applicable, may be obtained from the website Further information about the Company and the Fund including the prospectus www.vaneck.com and a paper copy is available, free of charge and upon request, and most recent annual reports and semi-annual reports is available free of at the registered office of the management company. The Company is subject to charge online at www.vaneck.com or on request at the registered office of the the tax laws and regulations of Ireland. Depending on your own country of company. These documents are available in English and certain other languages. residence, this may have an impact on your investment. Please consult your The Fund is a sub-fund of the Company, an umbrella fund structure comprisinginvestment or tax adviser for advice on your own tax liabilities. different sub-funds. This document is specific to the Fund stated at the beginning Further details regarding the Index are available on the Index Provider's website: of this document. However, the prospectus, annual and semi-annual reports are www.marketvector.com prepared for the Company rather than separately for the Fund. VanEck Asset Management B.V. may be held liable solely on the basis of any The net asset value and other information is available online at www.vaneck.com.statement contained in this document that is misleading, inaccurate or Investors can buy or sell shares daily on stock exchange(s) on which the shares inconsistent with the relevant parts of the prospectus of the Fund. are traded. The Fund shares are traded on one or more stock exchanges. Under Irish law, the Company has segregated liability between its sub-funds. The The details of the remuneration policy of the management company, VanEckFund’s assets will not be used to discharge the liabilities of other sub-funds of Asset Management B.V., including, but not limited to, a description of how the Company. In addition, the Fund’s assets and liabilities are segregated and remuneration benefits are calculated, the identities of persons responsible for held separately from the assets of other sub-funds. awarding the remuneration and benefits including the composition of the The Fund is authorized in Ireland and regulated by the Central Bank of Ireland (CBI). VanEck Asset Management B.V. is authorized in the Netherlands and regulated by the Dutch Authority for the Financial Markets (AFM). The key investor information is accurate as at 06 February 2025.